FLINT, Mich. – March 8, 2016 – The nation’s largest independent specialty pharmacy launches national campaign to drive awareness of multiple sclerosis and the impact on patients’ lives.

Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Multiple Sclerosis (MS) Awareness Week with a campaign to honor patients and caregivers. The company released a video of one of its patients to tell her personal story and call attention to MS.

Meet Bethany: Multiple Sclerosis

MS Awareness Week is celebrated to raise visibility of multiple sclerosis and the impact on patients’ lives. Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system and interrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling, to blindness, paralysis and cognitive difficulties. According to the National Multiple Sclerosis Society, most people diagnosed with MS are between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease.

“The real-life story of Bethany reveals the true spirit of the Diplomat Difference and the critical role that specialty pharmacy plays in managing some of the nation’s most complex patient cases,” said Diplomat CEO and Chairman Phil Hagerman. “At Diplomat, we’re committed to not only provide high-touch care through our specially designed programs, but also listen to patient stories and share their victories, whether they be large or small.”

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

 

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.

###

CONTACT:
Kali Lucas, Public Relations Coordinator
810.768.9580 | press@diplomat.is

 

Twitter